OBD has completed a clinical trial using the EpiSwitchTM technology, to stratify prostate cancer patients with the most aggressive prostate cancer that is at a high risk of spreading from those with less aggressive prostate cancer that can be suitably managed with less invasive treatments.This test will help physicians and patients to make better decisions about the patient’s treatment regime.